David D. Meek
CIK 1555337 · Chief Executive Officer · last filed 2026-06-18
David D. Meek is a Chief Executive Officer who has filed 41 SEC Form 4 insider transactions across 7 companies since 2012. The most recent filing, for CGEM, was dated Jun 18, 2026. Across all open-market trades the lifetime net is −$696.9K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$1.66M
7
41
-$696.9K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CGEM | Director | — | $17.13 | — | $0 | 3 | 2026-06-18 |
| QURE | Director | 41,740 | $39.71 | $1.66M | -$220.6K | 16 | 2026-06-12 |
| Fusion Pharmaceuticals Inc. (FUSN) Delisted | Director | — | $21.55 | — | $0 | 2 | 2024-06-04 |
| Mirati Therapeutics, Inc. (MRTX) Delisted | Chief Executive Officer | 151,171 | $58.70 | $8.87M | -$321.3K | 5 | 2023-01-24 |
| Entasis Therapeutics Holdings Inc. (ETTX) Delisted | Director | 0 | $2.19 | $0 | $0 | 6 | 2022-07-11 |
| Baxalta Inc (BXLT) Delisted | EVP and President, Oncology | 52,514 | — | — | $0 | 3 | 2016-03-07 |
| ENDOCYTE INC (ECYT) Delisted | Chief Commercial Officer | 7,500 | — | — | -$155.0K | 4 | 2014-02-10 |
Recent Filings
41 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-18 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2026-06-12 | QURE | Mixed | +5,557 | -$53.9K | EDGAR |
| 2026-06-11 | QURE | Notice (144) | −1,993 | -$53.9K | EDGAR |
| 2025-06-24 | QURE | Sell (S) | −2,112 | -$30.5K | EDGAR |
| 2025-06-16 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2025-06-13 | QURE | Grant (A) | +7,970 | $0 | EDGAR |
| 2024-06-21 | QURE | Grant (A) | +8,080 | $0 | EDGAR |
| 2024-06-17 | QURE | Sell (S) | −2,229 | -$11.4K | EDGAR |
| 2024-06-04 | Fusion Pharmaceuticals Inc. (FUSN) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-05-16 | CGEM | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.